A Phase 2 interventional study of VH4004280 and VH4011499 in HIV Infections, sponsored by ViiV Healthcare. Completed at 20 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 138th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 48 in phase 2, and was the 239th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of VH4004280 Dose Level 1 (low concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label antiretroviral therapy (ART) up to day 39.
Drug: VH4004280 · Drug: Antiretroviral therapy
Participants received a single dose of VH4004280 Dose Level 2 (medium concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: VH4004280 · Drug: Antiretroviral therapy
Participants received a single pre-specified dose of VH4004280 (high concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: VH4004280 · Drug: Antiretroviral therapy
Participants received a matching placebo for VH4004280 on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: VH4004280 Matching Placebo · Drug: Antiretroviral therapy
Participants received a single dose of VH4011499 Dose Level 1 (low concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants had the option to switch to an open-label ART up to day 39.
Drug: VH4011499 · Drug: Antiretroviral therapy
Participants received a single dose of VH4011499 Dose Level 2 (medium concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: VH4011499 · Drug: VH4011499 Matching Placebo · Drug: Antiretroviral therapy
Participants received a single pre-specified dose of VH4011499 (high concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: VH4011499 · Drug: Antiretroviral therapy
Participants received a matching placebo for VH4011499 on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.
Drug: Antiretroviral therapy
VH4004280 was administered as tablets orally at Day 1.
VH4011499 was administered as tablets orally at Day 1 and Day 6.
VH4004280 Matching Placebo was administered as tablets orally at Day 1.
VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
Antiretroviral therapy was administered as available and as per investigator's recommendation.
Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The results were expressed as log10 copies per milliliter (log10 c/mL).
Time frame: From Baseline (Day 1) and up to Day 11
Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: From Baseline (Day 1) and up to Day 11
Monotherapy: Number of Participants With Any Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.
Time frame: From Baseline (Day 1) and up to Day 11
Follow-up: Number of Participants With Any AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.
Time frame: From Day 11 and up to Day 39
Monotherapy: Number of Participants With AEs by Severity
Severity was rated according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.
Time frame: From Baseline (Day 1) and up to Day 11
Follow-up: Number of Participants With AEs by Severity
Severity was rated according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.
Time frame: From Day 11 and up to Day 39
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation
'Discontinuation' of study intervention refers to any participant who has not received all planned doses of study intervention.
Time frame: From Baseline (Day 1) and up to Day 11
Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.Standard deviation (SD) = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Alanine Aminotransferace (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Time frame: From Baseline (Day 1) and up to Day 39
Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Time frame: From Baseline (Day 1) and up to Day 39
Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Time frame: From Baseline (Day 1) and up to Day 39
Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Time frame: From Baseline (Day 1) and up to Day 39
Monotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax)
Cmax is defined as the maximum concentration of the drug in plasma.
Time frame: After dose administration at Day 1
Monotherapy, VH4011499: Cmax
Cmax is defined as the maximum concentration of the drug in plasma.
Time frame: After dose administration at Day 1 and Day 6
Monotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax)
Tmax is a measure of the time required to reach the maximum concentration of the drug.
Time frame: After dose administration at Day 1
Monotherapy, VH4011499: Tmax
Tmax is a measure of the time required to reach the maximum concentration of the drug.
Time frame: After dose administration at Day 1 and Day 6
Monotherapy, VH4004280: Plasma Concentration at Day 11 (C11)
C11 is defined as the concentration of the drug in plasma at Day 11.
Time frame: At Day 11
Monotherapy, VH4011499: C11
C11 is defined as the concentration of the drug in plasma at Day 11.
Time frame: At Day 11
Monotherapy, VH4004280: Change in Plasma HIV-1 RNA From Baseline
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: At Baseline (Day 1) and Day 11
Monotherapy, VH4011499: Change in Plasma HIV-1 RNA From Baseline
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: At Baseline (Day 1) and Day 11
| Milestone | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 3 | 7 | 6 | 7 | 3 |
| Completed | 6 | 6 | 6 | 3 | 7 | 6 | 7 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 3 | 7 | 6 | 7 | 3 |
| Completed | 6 | 6 | 6 | 3 | 7 | 6 | 7 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The results were expressed as log10 copies per milliliter (log10 c/mL).
| log10 c/mL | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 |
|---|---|---|---|---|
| Baseline (Day 1) | 5.004 ± 0.4592 | 4.923 ± 0.5428 | 4.866 ± 0.7696 | 4.636 ± 0.6641 |
| Maximum change compared to Baseline (Day 1) | -1.056 ± 0.4567 | -1.391 ± 0.6986 | -1.983 ± 0.2171 | -0.070 ± 0.0574 |
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| log10 c/mL | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|
| Baseline (Day 1) | 5.001 ± 0.7304 | 4.339 ± 0.6185 | 4.960 ± 0.7288 | 4.714 ± 0.7736 |
| Maximum change compared to Baseline (Day 1) | -1.834 ± 0.5141 | -1.797 ± 0.4544 | -2.165 ± 0.4310 | -0.176 ± 0.1969 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Monotherapy: Number of Participants With Any Adverse Events (AEs) | 3 | 2 | 2 | 2 | 2 | 4 | 2 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Follow-up: Number of Participants With Any AEs | 1 | 3 | 4 | 1 | 3 | 3 | 5 | 0 |
Severity was rated according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Grade 1 | 0 | 2 | 1 | 1 | 1 | 3 | 2 | 1 |
| Grade 2 | 3 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Severity was rated according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Grade 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 0 |
| Grade 2 | 0 | 1 | 3 | 1 | 1 | 2 | 3 | 0 |
| Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
'Discontinuation' of study intervention refers to any participant who has not received all planned doses of study intervention.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|---|---|---|---|
| Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation | — | — | — | — | 0 | 0 | 0 | 0 |
Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.Standard deviation (SD) = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
| Micromole per liter (µmol/L) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 |
|---|---|---|---|---|
| Total Bilirubin, Baseline (Day 1) | 6.641 ± 1.5157 | 8.408 ± 5.5383 | 6.926 ± 4.6300 | 6.783 ± 1.2370 |
| Total Bilirubin, Day 2 | -0.143 ± 1.7719 | -0.513 ± 2.9697 | 0.239 ± 4.4814 | 1.995 ± 3.5100 |
| Total Bilirubin, Day 4 | 0.547 ± 1.0073 | -2.081 ± 3.5614 | 1.984 ± 3.1078 | -1.767 ± 1.5516 |
| Total Bilirubin, Day 6 | -0.171 ± 3.5771 | 0.485 ± 3.6055 | 2.366 ± 5.2755 | 2.565 ± 2.8460 |
| Total Bilirubin, Day 7 | 1.539 ± 1.4307 | 0.941 ± 3.3295 | 0.599 ± 2.4774 | 1.767 ± 3.2189 |
| Total Bilirubin, Day 9 | 1.060 ± 2.5230 | 0.656 ± 4.2584 | 1.055 ± 1.7752 | 0.969 ± 3.7672 |
| Total Bilirubin, Day 11 | 1.154 ± 1.5758 | 1.539 ± 1.8670 | 0.085 ± 1.2649 | -0.171 ± 2.7360 |
| Total Bilirubin, Day 18 | 0.684 ± 2.6513 | 0.399 ± 2.4005 | -1.340 ± 3.2199 | -0.342 ± 1.8016 |
| Total Bilirubin, Day 25 | 0.570 ± 1.1731 | 0.513 ± 3.0049 | -2.195 ± 3.5417 | -0.741 ± 2.2771 |
| Total Bilirubin, Day 32 | 0.770 ± 2.1596 | -0.542 ± 2.5557 | -1.881 ± 3.4709 | 1.026 ± 3.6194 |
| Total Bilirubin, Day 39 | 0.923 ± 1.3712 | -1.197 ± 3.2910 | -0.513 ± 3.2332 | 0.456 ± 2.8682 |
| Direct Bilirubin, Baseline (Day 1) | 3.410 ± 0.0000 | 3.410 ± 0.0000 | 3.410 ± 0.0000 | 3.410 ± 0.0000 |
| Direct Bilirubin, Day 2 | 0.000 ± 0.0000 | 0.002 ± 0.0041 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 4 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.002 ± 0.0041 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 6 | 0.000 ± 0.0000 | 0.030 ± 0.0739 | 0.030 ± 0.0739 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 7 | 0.000 ± 0.0000 | 0.059 ± 0.1437 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 9 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 11 | 0.000 ± 0.0000 | 0.002 ± 0.0041 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 18 | 0.000 ± 0.0000 | 0.174 ± 0.4221 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 25 | 0.000 ± 0.0000 | 0.030 ± 0.0739 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 32 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Direct Bilirubin, Day 39 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
| µmol/L | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|
| Total Bilirubin, Baseline (Day 1) | 5.643 ± 2.4898 | 7.524 ± 2.6579 | 4.544 ± 1.7576 | 7.011 ± 2.2361 |
| Total Bilirubin, Day 2 | -0.928 ± 0.9095 | 0.114 ± 0.9951 | 0.611 ± 1.6008 | -0.855 ± 0.6165 |
| Total Bilirubin, Day 4 | 0.122 ± 2.3975 | -0.656 ± 0.9937 | 1.808 ± 2.3463 | -0.570 ± 1.5516 |
| Total Bilirubin, Day 6 | -0.171 ± 2.4741 | -1.967 ± 2.6286 | 0.440 ± 1.4370 | -2.109 ± 3.6529 |
| Total Bilirubin, Day 7 | 0.366 ± 3.4476 | -0.200 ± 2.7111 | 0.367 ± 1.4081 | -1.995 ± 3.6569 |
| Total Bilirubin, Day 9 | -0.440 ± 2.3774 | -0.228 ± 1.4004 | 1.099 ± 1.4804 | 0.912 ± 3.5924 |
| Total Bilirubin, Day 11 | 1.050 ± 2.0766 | -0.884 ± 1.3439 | 0.709 ± 2.3036 | -2.964 ± 1.2370 |
| Total Bilirubin, Day 18 | -0.366 ± 2.7081 | -0.057 ± 1.7989 | 0.586 ± 1.7739 | 1.083 ± 3.4427 |
| Total Bilirubin, Day 25 | 0.366 ± 3.9024 | 0.798 ± 3.2258 | 1.295 ± 2.1332 | -1.026 ± 3.0059 |
| Total Bilirubin, Day 32 | 0.599 ± 2.9175 | 0.513 ± 3.3017 | 1.075 ± 2.2398 | 0.627 ± 4.9452 |
| Total Bilirubin, Day 39 | 0.239 ± 1.3927 | -0.599 ± 1.7861 | 0.489 ± 2.2630 | -0.855 ± 0.2418 |
| Direct Bilirubin, Baseline (Day 1) | 3.485 ± 0.1977 | 3.410 ± 0.0000 | 3.705 ± 0.7794 | 3.527 ± 0.2032 |
| Direct Bilirubin, Day 2 | -0.075 ± 0.1977 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | -0.117 ± 0.2032 |
| Direct Bilirubin, Day 4 | -0.057 ± 0.1396 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | -0.114 ± 0.1975 |
| Direct Bilirubin, Day 6 | -0.073 ± 0.1939 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | -0.117 ± 0.2032 |
| Direct Bilirubin, Day 7 | -0.049 ± 0.2197 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | 1.140 ± 2.2862 |
| Direct Bilirubin, Day 9 | -0.075 ± 0.1977 | 0.002 ± 0.0041 | -0.295 ± 0.7794 | -0.057 ± 0.0987 |
| Direct Bilirubin, Day 11 | -0.073 ± 0.1983 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | -0.117 ± 0.2032 |
| Direct Bilirubin, Day 18 | -0.075 ± 0.1977 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | 0.057 ± 0.0987 |
| Direct Bilirubin, Day 25 | 0.027 ± 0.1571 | 0.030 ± 0.0739 | -0.295 ± 0.7794 | -0.114 ± 0.1975 |
| Direct Bilirubin, Day 32 | -0.057 ± 0.2395 | 0.230 ± 0.5626 | -0.295 ± 0.7794 | 0.114 ± 0.1975 |
| Direct Bilirubin, Day 39 | -0.087 ± 0.2135 | 0.000 ± 0.0000 | -0.295 ± 0.7794 | -0.171 ± 0.2418 |
Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| International units per liter (IU/L) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 |
|---|---|---|---|---|
| ALT, Baseline (Day 1) | 31.3 ± 13.59 | 21.7 ± 7.17 | 33.2 ± 13.23 | 52.7 ± 55.82 |
| ALT, Day 2 | -2.8 ± 3.25 | -1.8 ± 3.25 | -0.2 ± 3.56 | 15.0 ± 29.46 |
| ALT, Day 4 | -3.8 ± 4.09 | -2.3 ± 2.80 | 0.2 ± 6.10 | 4.7 ± 9.29 |
| ALT, Day 6 | -7.8 ± 9.33 | -1.3 ± 1.51 | 2.2 ± 8.13 | -13.7 ± 27.14 |
| ALT, Day 7 | -6.7 ± 9.77 | -2.0 ± 3.03 | 0.2 ± 7.39 | -19.3 ± 32.62 |
| ALT, Day 9 | -6.0 ± 13.69 | -0.7 ± 9.63 | 1.5 ± 12.10 | -20.7 ± 35.81 |
| ALT, Day 11 | -8.8 ± 15.78 | -2.0 ± 6.26 | -0.2 ± 11.99 | -16.7 ± 29.74 |
| ALT, Day 18 | -6.2 ± 14.16 | -0.2 ± 4.45 | 8.3 ± 27.46 | -15.7 ± 31.18 |
| ALT, Day 25 | -6.8 ± 15.48 | -0.5 ± 2.17 | 1.7 ± 14.54 | -27.7 ± 44.50 |
| ALT, Day 32 | -9.2 ± 11.97 | -0.3 ± 4.23 | 0.3 ± 12.32 | -33.0 ± 56.40 |
| ALT, Day 39 | -9.8 ± 11.12 | -0.3 ± 3.50 | -4.0 ± 8.72 | -33.0 ± 54.62 |
| ALP, Baseline (Day 1) | 79.2 ± 14.40 | 74.3 ± 15.74 | 71.7 ± 19.39 | 64.3 ± 16.80 |
| ALP, Day 2 | -1.3 ± 7.87 | -2.7 ± 10.03 | -1.0 ± 3.16 | -3.0 ± 3.00 |
| ALP, Day 4 | 0.6 ± 5.41 | -5.0 ± 5.90 | -2.6 ± 2.51 | -1.0 ± 3.61 |
| ALP, Day 6 | 1.5 ± 6.75 | -4.5 ± 6.35 | 0.7 ± 5.35 | -2.3 ± 1.15 |
| ALP, Day 7 | -0.2 ± 6.24 | -6.2 ± 2.71 | -2.0 ± 4.52 | -6.0 ± 4.36 |
| ALP, Day 9 | -0.2 ± 2.95 | -4.3 ± 6.09 | -3.5 ± 5.82 | -6.3 ± 6.66 |
| ALP, Day 11 | -5.0 ± 2.94 | -4.8 ± 6.05 | -5.8 ± 8.28 | -6.3 ± 4.93 |
| ALP, Day 18 | -0.5 ± 3.33 | -7.0 ± 5.40 | -2.7 ± 8.50 | -4.3 ± 4.51 |
| ALP, Day 25 | 1.0 ± 11.17 | -5.0 ± 4.69 | -1.3 ± 8.71 | -5.0 ± 4.36 |
| ALP, Day 32 | 3.2 ± 21.10 | -2.7 ± 10.84 | -3.8 ± 8.47 | -5.3 ± 5.77 |
| ALP, Day 39 | 0.6 ± 4.16 | -5.5 ± 7.82 | -2.2 ± 4.15 | 0.3 ± 3.51 |
| AST, Baseline (Day 1) | 26.0 ± 4.94 | 21.5 ± 4.23 | 27.2 ± 3.49 | 29.7 ± 11.72 |
| AST, Day 2 | -3.5 ± 3.62 | -0.8 ± 2.71 | -0.2 ± 4.09 | 11.0 ± 26.00 |
| AST, Day 4 | -3.6 ± 3.21 | -0.8 ± 0.75 | 0.8 ± 3.96 | -1.0 ± 5.29 |
| AST, Day 6 | -4.8 ± 4.36 | -2.0 ± 1.26 | 0.7 ± 5.54 | -8.3 ± 11.06 |
| AST, Day 7 | -4.8 ± 4.54 | -2.2 ± 2.23 | -1.2 ± 4.88 | -9.0 ± 9.85 |
| AST, Day 9 | -5.0 ± 6.00 | -1.5 ± 4.72 | 2.5 ± 8.53 | -9.3 ± 10.69 |
| AST, Day 11 | -6.3 ± 6.34 | -2.0 ± 4.60 | 7.0 ± 22.52 | -6.7 ± 5.03 |
| AST, Day 18 | -4.7 ± 6.44 | 0.0 ± 6.51 | 4.2 ± 16.46 | -1.0 ± 3.61 |
| AST, Day 25 | -4.7 ± 9.35 | -0.3 ± 3.56 | 1.5 ± 7.40 | -11.3 ± 11.93 |
| AST, Day 32 | -5.0 ± 6.81 | -1.3 ± 3.08 | 0.7 ± 4.72 | -9.0 ± 14.80 |
| AST, Day 39 | -6.6 ± 5.50 | 0.5 ± 3.39 | -2.4 ± 3.13 | -10.3 ± 13.65 |
Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| IU/L | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|
| ALT, Baseline (Day 1) | 14.9 ± 4.41 | 19.5 ± 9.03 | 31.7 ± 22.60 | 18.3 ± 2.08 |
| ALT, Day 2 | 1.7 ± 1.25 | -1.2 ± 1.83 | -1.6 ± 3.78 | 0.7 ± 0.58 |
| ALT, Day 4 | 2.4 ± 1.72 | -1.0 ± 3.85 | -3.6 ± 13.20 | -1.0 ± 1.00 |
| ALT, Day 6 | -0.1 ± 1.57 | -1.2 ± 3.76 | -5.1 ± 14.58 | 0.7 ± 1.15 |
| ALT, Day 7 | 0.1 ± 2.54 | -1.5 ± 4.76 | -7.3 ± 14.91 | -0.7 ± 1.57 |
| ALT, Day 9 | -0.3 ± 1.98 | -0.2 ± 4.07 | -8.0 ± 16.42 | -0.3 ± 2.08 |
| ALT, Day 11 | 0.0 ± 3.32 | -1.2 ± 3.76 | -7.3 ± 11.71 | 0.0 ± 3.61 |
| ALT, Day 18 | 0.3 ± 5.19 | -1.3 ± 4.46 | -4.0 ± 17.91 | 1.7 ± 2.52 |
| ALT, Day 25 | 2.0 ± 9.02 | 0.0 ± 5.66 | -7.4 ± 17.52 | 0.7 ± 0.58 |
| ALT, Day 32 | 4.0 ± 13.62 | -2.7 ± 3.88 | -10.3 ± 16.63 | 3.0 ± 4.36 |
| ALT, Day 39 | 0.0 ± 7.84 | 0.8 ± 4.49 | -3.6 ± 15.87 | 28.0 ± 28.28 |
| ALP, Baseline (Day 1) | 81.1 ± 14.55 | 68.2 ± 18.90 | 78.9 ± 20.69 | 89.3 ± 16.50 |
| ALP, Day 2 | 1.0 ± 5.60 | -1.2 ± 2.48 | 0.6 ± 6.48 | -0.3 ± 1.53 |
| ALP, Day 4 | 2.7 ± 6.97 | -2.5 ± 3.33 | -4.9 ± 13.38 | -0.7 ± 7.51 |
| ALP, Day 6 | -1.4 ± 7.44 | -3.7 ± 5.75 | -3.6 ± 4.69 | 6.3 ± 8.33 |
| ALP, Day 7 | 3.9 ± 5.70 | -4.5 ± 3.39 | -0.4 ± 8.66 | 4.0 ± 8.72 |
| ALP, Day 9 | 0.0 ± 9.80 | -1.5 ± 1.76 | -1.4 ± 9.76 | -0.7 ± 8.08 |
| ALP, Day 11 | 2.9 ± 13.32 | -1.3 ± 3.20 | -1.6 ± 7.96 | 10.3 ± 14.47 |
| ALP, Day 18 | -0.1 ± 6.01 | -3.2 ± 3.92 | -2.9 ± 6.49 | 2.3 ± 9.71 |
| ALP, Day 25 | 2.4 ± 7.59 | -5.0 ± 5.76 | -6.4 ± 10.97 | -1.7 ± 17.21 |
| ALP, Day 32 | 0.3 ± 9.05 | -4.5 ± 3.45 | -3.7 ± 9.81 | -2.3 ± 8.02 |
| ALP, Day 39 | -2.4 ± 13.72 | -2.2 ± 8.04 | -1.7 ± 14.69 | 1.0 ± 11.31 |
| AST, Baseline (Day 1) | 18.6 ± 3.87 | 24.0 ± 8.07 | 24.7 ± 7.20 | 27.7 ± 5.51 |
| AST, Day 2 | -0.7 ± 2.43 | -2.3 ± 2.80 | -2.0 ± 1.29 | -2.3 ± 3.21 |
| AST, Day 4 | 1.1 ± 4.45 | -2.7 ± 3.27 | 1.7 ± 7.50 | -2.3 ± 0.58 |
| AST, Day 6 | -0.9 ± 4.02 | -1.5 ± 5.68 | -2.4 ± 3.55 | -1.7 ± 3.21 |
| AST, Day 7 | -1.7 ± 4.07 | -3.5 ± 5.75 | -3.7 ± 5.12 | -5.7 ± 2.31 |
| AST, Day 9 | 0.0 ± 3.00 | -2.7 ± 4.41 | -4.3 ± 5.02 | -5.0 ± 6.24 |
| AST, Day 11 | -1.6 ± 3.74 | -2.2 ± 4.79 | -2.1 ± 3.29 | -4.7 ± 7.51 |
| AST, Day 18 | -1.3 ± 5.82 | -3.2 ± 5.31 | 2.4 ± 9.55 | -0.3 ± 5.51 |
| AST, Day 25 | 1.6 ± 5.86 | -0.5 ± 4.32 | -2.6 ± 4.86 | -3.7 ± 0.58 |
| AST, Day 32 | 2.8 ± 9.97 | -1.4 ± 3.13 | -2.9 ± 6.69 | -2.3 ± 4.93 |
| AST, Day 39 | 0.0 ± 5.43 | 1.3 ± 2.58 | 1.7 ± 10.64 | 23.0 ± 5.66 |
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 |
|---|---|---|---|---|
| Total Bilirubin, Increase to Grade 1 | 0 | 1 | 0 | 0 |
| Total Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
| Participants | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|
| Total Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 1 |
| Direct Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
| Participants | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 |
|---|---|---|---|---|
| ALT, Increase to Grade 1 | 1 | 0 | 1 | 0 |
| ALT, Increase to Grade 2 | 0 | 0 | 1 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 1 | 1 | 0 | 1 | 1 |
| AST, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
| Participants | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 |
|---|---|---|---|---|
| ALT, Increase to Grade 1 | 0 | 0 | 1 | 1 |
| ALT, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 1 | 0 | 0 | 0 | 1 |
| AST, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Cmax is defined as the maximum concentration of the drug in plasma.
| Nanogram per milliliter (ng/mL) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose |
|---|---|---|---|
| Monotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax) | 131.57 ± 77.68 | 364.70 ± 85.21 | 473.00 ± 54.23 |
Cmax is defined as the maximum concentration of the drug in plasma.
| ng/mL | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose |
|---|---|---|---|
| Day 1 | 27.63 ± 94.53 | 31.88 ± 26.58 | 133.59 ± 42.34 |
| Day 6 | 35.30 ± 81.31 | 32.31 ± 25.97 | 141.18 ± 47.79 |
Tmax is a measure of the time required to reach the maximum concentration of the drug.
| Hour (h) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose |
|---|---|---|---|
| Monotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax) | 7.95 (6.0 to 9.7) | 9.00 (6.0 to 11.6) | 8.04 (6.0 to 10.0) |
Tmax is a measure of the time required to reach the maximum concentration of the drug.
| h | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose |
|---|---|---|---|
| Day 1 | 9.95 (6.0 to 12.0) | 9.88 (8.1 to 10.1) | 8.00 (4.1 to 12.0) |
| Day 6 | 10.00 (8.0 to 26.9) | 10.04 (8.0 to 11.6) | 11.52 (6.0 to 24.1) |
C11 is defined as the concentration of the drug in plasma at Day 11.
| ng/mL | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose |
|---|---|---|---|
| Monotherapy, VH4004280: Plasma Concentration at Day 11 (C11) | 18.07 ± 132.07 | 48.53 ± 130.33 | 50.42 ± 41.52 |
C11 is defined as the concentration of the drug in plasma at Day 11.
| ng/mL | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose |
|---|---|---|---|
| Monotherapy, VH4011499: C11 | 11.16 ± 50.02 | 10.56 ± 36.61 | 27.04 ± 50.68 |
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| log10 c/mL | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose |
|---|---|---|---|
| Baseline (Day 1) | 5.004 ± 0.4592 | 4.923 ± 0.5428 | 4.866 ± 0.7696 |
| Day 11 | -0.941 ± 0.6608 | -1.322 ± 0.7727 | -1.939 ± 0.1124 |
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| log10 c/mL | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose |
|---|---|---|---|
| Baseline (Day 1) | 5.001 ± 0.7304 | 4.339 ± 0.6185 | 4.960 ± 0.7288 |
| Day 11 | -1.801 ± 0.5165 | -1.750 ± 0.4962 | -2.165 ± 0.4310 |
Collected over All-cause mortality, SAEs and non-serious AEs (including solicited and unsolicited events) were assessed from Day 1 [Monotherapy Phase] and up to Day 39 [Follow-up Phase].. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1a: VH4004280 Dose Level 1 (Monotherapy) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1a: VH4004280 Dose Level 2 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2a: VH4004280 Pre-specified Dose (Monotherapy) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Matching Placebo for VH4004280 (Monotherapy) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 1b: VH4011499 Dose Level 1 (Monotherapy) | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part 1b: VH4011499 Dose Level 2 (Monotherapy) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 2b: VH4011499 Pre-specified Dose (Monotherapy) | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Matching Placebo for VH4011499 (Monotherapy) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Part 1a: VH4004280 Dose Level 1 (Follow-up) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1a: VH4004280 Dose Level 2 (Follow-up) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2a: VH4004280 Pre-specified Dose (Follow-up) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Matching Placebo for VH4004280 (Follow-up) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Part 1b: VH4011499 Dose Level 1 (Follow-up) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Part 1b: VH4011499 Dose Level 2 (Follow-up) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2b: VH4011499 Pre-specified Dose (Follow-up) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Matching Placebo for VH4011499 (Follow-up) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | Part 1a: VH4004280 Dose Level 1 (Monotherapy) | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose (Monotherapy) | Matching Placebo for VH4004280 (Monotherapy) | Part 1b: VH4011499 Dose Level 1 (Monotherapy) | Part 1b: VH4011499 Dose Level 2 (Monotherapy) | Part 2b: VH4011499 Pre-specified Dose (Monotherapy) | Matching Placebo for VH4011499 (Monotherapy) | Part 1a: VH4004280 Dose Level 1 (Follow-up) | Part 1a: VH4004280 Dose Level 2 (Follow-up) | Part 2a: VH4004280 Pre-specified Dose (Follow-up) | Matching Placebo for VH4004280 (Follow-up) | Part 1b: VH4011499 Dose Level 1 (Follow-up) | Part 1b: VH4011499 Dose Level 2 (Follow-up) | Part 2b: VH4011499 Pre-specified Dose (Follow-up) | Matching Placebo for VH4011499 (Follow-up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vessel puncture site haematomaGeneral disorders | 0/6 | 0/6 | 0/6 | 1/3 | 0/7 | 1/6 | 2/7 | 0/3 | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| Drug hypersensitivityImmune system disorders | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 1/3 | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| Genital herpesInfections and infestations | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 | 0/6 | 0/6 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| InfluenzaInfections and infestations | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 | 0/6 | 0/6 | 0/6 | 1/3 | 1/7 | 0/6 | 0/7 | 0/3 |
| Blood creatinine increasedInvestigations | 0/6 | 2/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 | 0/6 | 2/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| Transaminases increasedInvestigations | 0/6 | 0/6 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/3 | 1/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 1/7 | 0/3 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 | 0/6 | 2/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 1/3 | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 0/6 | 0/3 | 1/7 | 1/6 | 1/7 | 1/3 | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/3 | 0/6 | 0/6 | 0/6 | 0/3 | 0/7 | 0/6 | 2/7 | 0/3 |
Baseline measures are presented based on Exposed population, which included all participants that received a study intervention.
| Age, Continuous(YEARS) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 34.3 ± 12.82 | 42.8 ± 10.3 | 31.5 ± 9.75 | 28.7 ± 9.29 | 31.6 ± 9.29 | 49.3 ± 7.45 | 28.6 ± 9.93 | 26 ± 2.65 | 34.8 ± 11.6 |
| Sex/Gender, Customized(Participants) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male | 5 | 5 | 6 | 2 | 7 | 3 | 6 | 3 | 37 |
| Female | 1 | 1 | 0 | 1 | 0 | 3 | 1 | 0 | 7 |
| Race/Ethnicity, Customized(Participants) | Part 1a: VH4004280 Dose Level 1 | Part 1a: VH4004280 Dose Level 2 | Part 2a: VH4004280 Pre-specified Dose | Matching Placebo for VH4004280 | Part 1b: VH4011499 Dose Level 1 | Part 1b: VH4011499 Dose Level 2 | Part 2b: VH4011499 Pre-specified Dose | Matching Placebo for VH4011499 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 4 |
| Black or African American | 1 | 2 | 2 | 0 | 0 | 3 | 0 | 1 | 9 |
| White | 5 | 4 | 4 | 3 | 7 | 3 | 3 | 2 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to: https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.viiv-studyregister.com
Ran from Oct 2023 to primary completion in Jun 2024, 7 months.
Results were first posted in Sep 2025, 1 year 3 months after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 7 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: VH4004280 · Dezecapavir